Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Akebia Therapeutics
(NQ:
AKBA
)
1.530
+0.060 (+4.08%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Akebia Therapeutics
< Previous
1
2
3
4
5
6
Next >
See Why Does HC Wainwright Maintain Neutral On Akebia Stock
April 07, 2022
Akebia Therapeutics Inc (NASDAQ: AKBA) announced three poster presentations at the National Kidney Foundation (NKF) Spring Clinical Meetings 2022.
Via
Benzinga
FDA Places Partial Hold On Vadadustat Pediatric Studies, Akebia Cuts Over 40% Staff
April 07, 2022
Via
Benzinga
Stocks That Hit 52-Week Lows On Monday
April 04, 2022
On Monday, 78 companies set new 52-week lows. Key Facts About Today's 52-Week Lows: Citigroup (NYSE:C) was the biggest company by market cap to set a new 52-week low....
Via
Benzinga
FDA Rejects Akebia Therapeutics' Vadadustat For CKD-Associated Anemia
March 30, 2022
Via
Benzinga
Earnings Scheduled For March 1, 2022
March 01, 2022
Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter. • TG Therapeutics (NASDAQ:TGTX) is estimated...
Via
Benzinga
The Week Ahead In Biotech (April 3-April 9): BioXcel FDA Decision, Neurology Conference Presentations Take The Spotlight
April 03, 2022
Biopharma stocks outperformed the broader market in the week ending April 2, thereby recouping the losses from the previous week. Clinical readouts and FDA decisions were among the chief catalysts that...
Via
Benzinga
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Akebia Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action AKBA
April 02, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates
April 01, 2022
Biopharma stocks are sensitive to a key binary event called the PDUFA date, the date by which the Food and Drug Administration is required to give its verdict on a regulatory application filed with...
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
April 01, 2022
On Friday, 111 companies set new 52-week lows. Interesting Points From Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was Citigroup (...
Via
Benzinga
53 Biggest Movers From Yesterday
April 01, 2022
Gainers Longeveron Inc. (NASDAQ: LGVN) shares jumped 105.4% to close at $13.80 on Thursday after the company announced the publication of results from a Phase 1 trial testing...
Via
Benzinga
6 Stocks Halted In Wednesday's Session
March 30, 2022
A circuit breaker is an automatic, temporary trading halt on certain securities when the underlying stock is experiencing times of high volatility. It is a measure put in place to...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
March 30, 2022
Gainers Adagio Therapeutics (NASDAQ:ADGI) shares rose 40.0% to $5.39 during Wednesday's regular session. Trading volume for this security as of 13:31 EST is 80.0...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2022
March 31, 2022
Upgrades
Via
Benzinga
NASDAQ:AKBA Investor Notice: Lawsuit Alleges Securities Laws Violations by Akebia Therapeutics, Inc.
March 30, 2022
San Diego, CA -- (SBWIRE) -- 03/30/2022 -- An investor, who purchased shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA), filed a lawsuit over alleged violations of Federal Securities Laws by Akebia...
Via
SBWire
35 Stocks Moving In Wednesday's Mid-Day Session
March 30, 2022
Gainers Direct Digital Holdings, Inc. (NASDAQ: DRCT) shares jumped 82.6% to $4.71 after the company reported a year over year increase in Q4 sales results and issued Q1 sales...
Via
Benzinga
51 Biggest Movers From Yesterday
March 31, 2022
Gainers Forge Global Holdings, Inc. (NYSE: FRGE) jumped 73.9% to close at $37.64. Direct Digital Holdings, Inc. (NASDAQ: DRCT) shares surged 60.5% to close at $4.14 on Wednesday...
Via
Benzinga
The Daily Biotech Pulse: Sanofi-IGM Ink Antibody Drug Collaboration; NeoGenomics Sinks On CEO Departure, Q1 Warning; Decision Day For Akebia
March 29, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More
March 27, 2022
Biotech stocks reversed course in the week ending March 25, as an increase in risk appetite prompted traders to move money out of defensives and into risky bets.
Via
Benzinga
Bronstein, Gewirtz & Grossman, LLC Notifies Akebia Therapeutics, Inc. (AKBA) Shareholders of Class Action and Encourages Investors to Contact the Firm
March 22, 2022
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
ROSEN, A LEADING LAW FIRM, Encourages Akebia Therapeutics, Inc. Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action – AKBA
March 21, 2022
From
The Rosen Law Firm, P.A.
Via
Business Wire
AKEBIA ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Akebia Therapeutics, Inc. and Encourages Investors to Contact the Firm
March 17, 2022
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
AKBA EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Akebia Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – AKBA
March 15, 2022
From
Rosen Law Firm
Via
Business Wire
7 Biotech Stocks With Key Catalysts in March
March 09, 2022
These seven stocks have some key catalysts lined up for March with the potential to move their price actions in big ways.
Via
InvestorPlace
Akebia Therapeutics Earnings Perspective: Return On Capital Employed
March 03, 2022
Benzinga Pro data, Akebia Therapeutics (NASDAQ:AKBA) reported Q4 sales of $59.60 million. Earnings fell to a loss of $70.68 million, resulting in a 18.7% decrease from last...
Via
Benzinga
Attention Biotech Investors: Mark Your Calendar For March PDUFA Dates
March 02, 2022
The Food and Drug Administration approval calendar was light in February. Nevertheless, the month saw regulatory nods accorded to some breakthrough therapies. Agios...
Via
Benzinga
Recap: Akebia Therapeutics Q4 Earnings
March 01, 2022
Akebia Therapeutics (NASDAQ:AKBA) reported its Q4 earnings results on Tuesday, March 1, 2022 at 08:00 AM. Here's what investors need to know about the announcement. Earnings...
Via
Benzinga
7 Speculative Penny Stocks Worth a Roll of the Dice
February 25, 2022
Under any circumstance, penny stocks are extremely risky. However, their under-the-radar profile could be intriguing right now.
Via
InvestorPlace
The Daily Biotech Pulse: Kodiak Sinks On Adverse Study Outcome, Marinus Flags Delay In Clinical Trial, Mainz Biomed Gains On Positive Regulatory Development
February 23, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kodiak's Wet AMD Treatment KSI-301 Did Not Meet Primary Endpoint In Phase...
Via
Benzinga
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Akebia Therapeutics, Inc. (AKBA) Investigation
January 27, 2022
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Canadian Biotech Disruptor Lexston Life Sciences is unlocking the God Molecule (LEXTF, ICPT, AKBA, QURE, BNTX, SAVA)
January 19, 2022
Via
AB Newswire
Topics
Bonds
Stocks
Exposures
Debt Markets
US Equities
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.